Epstein Barr Virus shedding in Multiple Sclerosis: Similar frequencies of EBV in saliva across separate patient cohorts

Holden, David, Gold, Julian, Hawkes, Christopher, Giovannoni, Gavin, Saxton, John, Carter, Anouska and Sharrack, Basil (2018) Epstein Barr Virus shedding in Multiple Sclerosis: Similar frequencies of EBV in saliva across separate patient cohorts. Multiple Sclerosis and Related Disorders, 25. pp. 197-199. ISSN 2211-0348

[img] Text (Full text)
Holden et al - Epstein Barr Virus shedding in Multiple Sclerosis AAM.pdf - Accepted Version
Restricted to Repository staff only until 27 July 2019.

Download (689kB)
Official URL: http://dx.doi.org/10.1016/j.msard.2018.07.041

Abstract

Background
Epstein Barr Virus (EBV) infection is closely associated with multiple sclerosis (MS), but the relationship between viral load and disease activity is unclear. This study tested the observed levels of salivary EBV in MS, as a first step in investigating this relationship.

Methods
Real-time quantitative PCR (qPCR) was used to measure EBV DNA levels in saliva samples from three separate Multiple Sclerosis (MS) patient cohorts.

Results
The qPCR assay was used to delineate EBV shedding, defined here as a reliably detectable level of extracellular EBV DNA in saliva. Frequency of EBV shedding was found to be similar across the groups, with 20-25% of subjects releasing virus on any given sampling date.

Diurnal variation in EBV count was tested in one of the cohorts, in which 26% of subjects showed more than a 10-fold difference between the highest and lowest EBV levels on a single day. In the same cohort, elevated viral levels at one time point did not predict elevated viral levels at a subsequent time point.

Conclusions
These results indicate that EBV lytic activity in a subject cannot be inferred from a single measure of EBV in saliva. Also, subjects do not appear to be behave constantly as “EBV shedders” or “non-shedders”. The assay is useful in giving a clear indication of salivary gland EBV lytic activity across a patient cohort – for example, in testing anti-viral drugs in MS.

Item Type: Article
Subjects: A300 Clinical Medicine
C500 Microbiology
Department: Faculties > Health and Life Sciences > Sport, Exercise and Rehabilitation
Depositing User: Paul Burns
Date Deposited: 27 Jul 2018 12:40
Last Modified: 11 Dec 2018 12:15
URI: http://nrl.northumbria.ac.uk/id/eprint/35150

Actions (login required)

View Item View Item

Downloads

Downloads per month over past year

View more statistics


Policies: NRL Policies | NRL University Deposit Policy | NRL Deposit Licence